CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Jun. 30, 2016	Jun. 30, 2015
Revenues:
License and milestone fees	$ 5,152	$ 79,469	$ 26,915	$ 57,815
Royalty revenue			195	13,867
Non-cash royalty revenue related to the sale of future royalties	12,894	28,142	25,299	5,484
Research and development support	2,781	3,482	4,014	2,848
Clinical materials revenue	679	4,354	3,579	5,527
Total revenues	21,506	115,447	60,002	85,541
Operating Expenses:
Research and development	66,566	139,739	148,077	111,768
General and administrative	17,995	33,911	36,916	28,228
Restructuring charge	4,431	779
Total operating expenses	88,992	174,429	184,993	139,996
Loss from operations	(67,486)	(58,982)	(124,991)	(54,455)
Investment income, net	259	1,146	325	69
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(8,665)	(13,682)	(20,130)	(5,437)
Interest expense on convertible senior notes	(2,249)	(3,040)	(138)
Non-cash debt conversion expense		(22,915)
Other income (expense), net	(742)	1,461	117	(916)
Net loss	$ (78,883)	$ (96,012)	$ (144,817)	$ (60,739)
Basic and diluted net loss per common share (in dollar per share)	$ (0.91)	$ (0.98)	$ (1.67)	$ (0.71)
Basic and diluted weighted average common shares outstanding (in shares)	87,102	98,068	86,976	86,038
Total comprehensive loss	$ (78,883)	$ (96,012)	$ (144,817)	$ (60,739)